Jazz Pharmaceuticals plc completed the divestiture of Sunosi (solriamfetol) in the United States. to Axsome Therapeutics Inc.
Centene Corp. agreed to divest two pharmacy businesses for about $2.8 billion, in line with the health insurer’s strategy to exit the pharmacy benefit management space.
Four years after partnering with GammaDelta Therapeutics to develop therapies for solid tumors, Takeda Pharmaceutical pulled the trigger and exercised its option to acquire the London-based company.
Takeda Pharmaceutical will divest Takeda Consumer Healthcare Company Limited (TCHC) to The Blackstone Group for $2.3 billion as the company continues to divest non-core business units in order to pare down debt accumulated from its $62 billion acquisition of Shire Plc.
Shareholders of Japan’s Takeda Pharmaceutical voted to approve the acquisition of Ireland’s Shire for about $58 billion.
Dynavax Technologies shares fell more than 5 percent after the company reported that an asthma drug being jointly developed with AstraZeneca failed to meet endpoints in a mid-stage trial.
Grünenthal will pay AstraZeneca $700 million up-front for the prescription drug rights to the acid-reflux medicine Nexium. AstraZeneca may also receive future milestones and sales-related payments of up to $90 million.
Novartis agreed to sell selected portions of its Sandoz U.S. portfolio, specifically the Sandoz U.S. dermatology business and generic U.S. oral solids portfolio, to Aurobindo Pharma USA for $900 million in cash plus $100 million in potential earn-outs.
Teva Pharmaceutical announced a comprehensive restructuring plan that includes the elimination of 25 percent of the company’s global workforce.
Boehringer Ingelheim agreed to divest five types of animal health products to settle charges that a proposed asset swap with Sanofi would harm competition.